HOME >> BIOLOGY >> NEWS
First Selenium-Based Orally-Active Antihypertensive May Lead To New Family Of Therapeutic Agents

Researchers at the Georgia Institute of Technology, in collaboration with colleagues at Mercer University, have developed what are believed to be the first orally active selenium-based antihypertensive compounds.

Beyond their potential value in treating high blood pressure, the phenylaminoalkyl selenide compounds could also point the way toward other selenium-based therapeutic agents -- and help expand knowledge of the role this trace element plays in human health.

Development and testing of the patented compounds, which have been studied so far only in animals, are reported in the November issue of The Journal of Pharmacology and Experimental Therapeutics.

"We think our antihypertensive compounds are the first in which biological activity is a consequence of the unique chemistry and biochemistry of selenium," explained Dr. Sheldon W. May, Regents' Professor in Georgia Tech's School of Chemistry and Biochemistry. "We look at this as a paradigm for understanding selenium's chemistry and biochemistry and using that knowledge to incorporate selenium into rationally designed molecules that could have therapeutic potential for many different applications."

Researchers Use Rational Drug Design Techniques

Using rational design techniques, the research team developed a series of derivatives based on their original selenium-based antihypertensive compound. The derivatives were designed to minimize absorption into the central nervous system and to resist damage from enzymes in the gastrointestinal tract.

The biochemistry and pharmacology of selenium are subjects of intense current interest because of evidence that a deficiency of the trace nutrient may play a role in diseases as diverse as cancer, heart disease, arthritis and AIDS. Selenium is an
'"/>

Contact: John Toon
john.toon@edi.gatech.edu
404-894-6986
Georgia Institute of Technology Research News
11-Nov-1997


Page: 1 2 3 4

Related biology news :

1. First glimpse of DNA binding to viral enzyme
2. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
3. 2nd media alert First Scientific Conference on Childhood Leukaemia
4. First International Scientific Conference on Childhood Leukaemia
5. First ever standards linking climate change, biodiversity and poverty seek global peer review
6. First genetic comparison of purebred domestic dogs produces surprises
7. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
8. First target for childhood malaria vaccine
9. First study of resveratrol dietary supplement finds effect on breast and prostate cancers unlikely
10. First flavors form a lasting impression
11. STN International launches Derwent World Patents Index First View

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/3/2020)... ... August 03, 2020 , ... Accumen Inc. ... with medical equipment manufacturer, Spectrum Solutions, to provide COVID-19 saliva testing kits nationally. ... supply chain for more than 10 years. Early in the COVID-19 crisis, we ...
(Date:7/18/2020)... ... July 17, 2020 , ... Commercial launch readiness is a critical ... discover a COVID cure or vaccine, the global economic downturn will only increase price ... not going away and capturing full value from every product launch is critical. However, ...
(Date:7/2/2020)... (PRWEB) , ... July 02, ... ... Biology Systems, B.V. (MBS) has announced a publication detailing the use of ... reverse transcription polymerase chain reaction (RT-PCR) in 16 minutes. The article, titled ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra , a leading ... food industries, is pleased to announce that Charles Galea has joined its clinical ... Charles is an accomplished and results-driven sales executive with over 10 years of ...
(Date:7/10/2020)... , ... July 09, 2020 ... ... company, announced today that Massachusetts Institute of Technology (MIT) has expanded the ... license allows PathSensors to move into the point-of-care diagnostic market, focusing initially ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief ... clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson serves as an ...
(Date:7/7/2020)... ... , ... Bio-IT World has announced the winners of the ... of Chicago, Massachusetts General Hospital, Mission: Cure, and the Pistoia Alliance were honored. ... examples of how technology innovations and strategic initiatives can be powerful forces for ...
Breaking Biology Technology:
Cached News: